000 01315 a2200409 4500
005 20250514221011.0
264 0 _c20050412
008 200504s 0 0 eng d
022 _a0001-6314
024 7 _a10.1111/j.1600-0404.2005.00378.x
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aLavrnic, D
245 0 0 _aCyclosporine in the treatment of myasthenia gravis.
_h[electronic resource]
260 _bActa neurologica Scandinavica
_cApr 2005
300 _a247-52 p.
_bdigital
500 _aPublication Type: Clinical Trial; Journal Article
650 0 4 _aAdult
650 0 4 _aCyclosporine
_xadverse effects
650 0 4 _aPersons with Disabilities
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aImmunosuppressive Agents
_xadverse effects
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aMyasthenia Gravis
_xdrug therapy
650 0 4 _aSeverity of Illness Index
650 0 4 _aTreatment Outcome
700 1 _aVujic, A
700 1 _aRakocevic-Stojanovic, V
700 1 _aStevic, Z
700 1 _aBasta, I
700 1 _aPavlovic, S
700 1 _aTrikic, R
700 1 _aApostolski, S
773 0 _tActa neurologica Scandinavica
_gvol. 111
_gno. 4
_gp. 247-52
856 4 0 _uhttps://doi.org/10.1111/j.1600-0404.2005.00378.x
_zAvailable from publisher's website
999 _c15414674
_d15414674